I first mentioned imaging of heart failure patients with metiodobenzylguanidine (AdreView) here. Now JACC has published a review summarizing the state of the art of MIBG imaging:
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.
No comments:
Post a Comment